Here's the pdf for this presentation: Inherited T790M EGFR Mutation

How should we conduct trials of targeted therapies in lung cancer if large randomized trials require hundreds to thousands of patients, cost millions of dollars and years to conduct, but are extremely likely to have negative results and will require a more refined population with a prospectively defined target? We'll tackle that question in our upcoming #LCSM chat on Thursday, March 27th at 8 PM ET, 5 PM PT. Topics will include:

Here is a brief and basic summary of the concept of why we're concerned not only about the cancer we can see but the potential cancer we can't.

One of the challenges of cancer care is that we guide our treatments by what clinical trial evidence tells us is best for particular patient populations. However, trials exclude patients who have significant medical issues other than cancer.

This week, the American Academy of Family Physicians (AAFP) elected to not follow the lead of the more influential US Preventive Services Task Force (USPSTF), which previously reviewed the information on chest CT screening for high risk patients and recommended it, and

Every few months I see a patient who reminds me of the fallability of mutation testing.

The end of a year is always a time for reflection on the past alongside hope for the future, so our upcoming lung cancer social media tweet chat on twitter (#LCSM on twitter) will focus on everyone's thoughts of the most significant developments in lung cancer over the past year, along with predictions and hopes for the coming year.

Please join us Thursday, January 2nd at 8 PM Eastern, 5 PM Pacific on Twitter, using the hashtag #LCSM to follow and add to our one-hour chat with the global lung cancer community, where we'll cover the following three questions:

Dr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer.

[powerpress]

For all too many people with lung cancer or caring for someone with it, the concept that lung cancer may not be threatening may seem sacrilegious.  It is, after all, by far the leading cause of cancer deaths in the US in both men and women, far ahead of both breast cancer and prostate cancer in its fatality rate, though breast cancers and prostate cancers are more commonly diagnosed in women and men respectively.

Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

[powerpress]